Potent Anti-Mesothelioma Activity by the Novel Naftopidil Analogue HUHS1015; Preclinical Evidence for Treatment

被引：0
|
作者：
Kuribayashi, Kozo [1 ]
Ieki, Ryuji [1 ]
Otsuki, Taiichiro [1 ]
Gotoh, Akinobu [2 ]
Tanaka, Akito [3 ]
Nishizaki, Tomoyuki [4 ]
Nakano, Takashi [1 ]
机构：
[1] Hyogo Coll Med, Dept Internal Med, Div Resp Med, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Inst Adv Med Sci, Lab Cell & Gene Therapy, Nishinomiya, Hyogo 6638501, Japan
[3] Hyogo Univ Hlth Sci, Adv Med Res Ctr, Lab Chem Biol, Kobe, Hyogo, Japan
[4] Hyogo Coll Med, Dept Physiol, Nishinomiya, Hyogo 6638501, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Naftopidil; anticancer drug; apoptosis; Malignant pleural mesotelioma (MPM);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI25.03
引用
收藏
页码：S352 / S352
页数：1
相关论文
共 45 条
  • [21] NCX-1015, a novel nitric oxide-releasing derivative of prednisolone, combines potent anti-inflammatory activity and low toxicity in the rat stomach subjected to ischemia-reperfusion.
    Peskar, BM
    Maricic, N
    Ehrlich, K
    Sawka, N
    GASTROENTEROLOGY, 2002, 122 (04) : A229 - A230
  • [22] Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies
    Thompson, Peggy A.
    Eam, Boreth
    Young, Nathan P.
    Fish, Sarah
    Chen, Joan
    Barrera, Maria
    Howard, Haleigh
    Parra, Ana
    Molter, Jolene
    Staunton, Jocelyn
    Hung, Ivy N. J.
    Parker, Greg S.
    Chiang, Gary G.
    Wegerski, Chris J.
    Nevarez, Andres
    Clarine, Jeff
    Sperry, Sam
    Xiang, Alan
    Tran, Chinh
    Nilewski, Christian
    Packard, Garrick K.
    Michels, Theodore
    Sprengeler, Paul A.
    Ernst, Justin T.
    Reich, Siegfried H.
    Webster, Kevin R.
    BLOOD, 2017, 130
  • [23] A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
    Ponath, Paul
    Menezes, Daniel
    Pan, Chin
    Chen, Bing
    Oyasu, Miho
    Strachan, Debbie
    LeBlanc, Heidi
    Sun, Huadong
    Wang, Xi-Tao
    Rangan, Vangipuram S.
    Deshpande, Shrikant
    Cristea, Sandra
    Park, Kwon-Sik
    Sage, Julien
    Cardarelli, Pina M.
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5178 - 5189
  • [24] Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models
    Stefka, Andrew
    Johnson, David
    Rosebeck, Shaun
    Park, Jae-Hyun
    Nakamura, Yusuke
    Jakubowiak, Andrzej J.
    BLOOD, 2017, 130
  • [25] A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
    Urara Tomita
    Yoko Ishimoto
    Masaki Ri
    Yumi Kawase
    Yoshiyuki Hizukuri
    Chikako Maru
    Kayoko Nanai
    Ryuichi Nakamura
    Makiko Nakayama
    Keiko Oguchi-Oshima
    Hiroyuki Sumi
    Toshiaki Ohtsuka
    Shinsuke Iida
    Toshinori Agatsuma
    Scientific Reports, 14
  • [26] HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
    Ke, Hang
    Zhang, Faming
    Wang, Jingjing
    Xiong, Lingxin
    An, Xiaoyu
    Tu, Xiaolong
    Chen, Cen
    Wang, Yueying
    Mao, Binchen
    Guo, Sheng
    Ju, Cunxiang
    He, Xiangfei
    Sun, Ruilin
    Zhang, Lei
    O'Connor, Owen A.
    Li, Qi-Xiang
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [27] HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
    Hang Ke
    Faming Zhang
    Jingjing Wang
    Lingxin Xiong
    Xiaoyu An
    Xiaolong Tu
    Cen Chen
    Yueying Wang
    Binchen Mao
    Sheng Guo
    Cunxiang Ju
    Xiangfei He
    Ruilin Sun
    Lei Zhang
    Owen A. O’Connor
    Qi-Xiang Li
    Scientific Reports, 13
  • [28] Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models
    Caenepeel, Sean R.
    Belmontes, Brian
    Sun, Jan
    Coxon, Angela
    Moody, Gordon
    Hughes, Paul E.
    CANCER RESEARCH, 2017, 77
  • [29] A novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
    Tomita, Urara
    Ishimoto, Yoko
    Ri, Masaki
    Kawase, Yumi
    Hizukuri, Yoshiyuki
    Maru, Chikako
    Nanai, Kayoko
    Nakamura, Ryuichi
    Nakayama, Makiko
    Oguchi-Oshima, Keiko
    Sumi, Hiroyuki
    Ohtsuka, Toshiaki
    Iida, Shinsuke
    Agatsuma, Toshinori
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [30] Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
    Patwardhan, Parag P.
    Ivy, Kathryn S.
    Musi, Elgilda
    de Stanchina, Elisa
    Schwartz, Gary K.
    ONCOTARGET, 2016, 7 (04) : 4093 - 4109
12345